Is either Thymalin or thymosin α1 FDA-approved?

No. Thymalin is used in Russia as an immunomodulator; not FDA-approved, sold as a gray-market research-use-only injectable. Thymosin α1 is approved as Zadaxin in dozens of countries; not FDA-approved in the US.

Which has stronger human evidence, Thymalin or thymosin α1?

Neither clearly. Both have human clinical data. The key source for Thymalin is Khavinson, Neuro Endocrinol Lett 2003; for thymosin α1, it is ETASS sepsis RCT, Crit Care 2013.

What are the main safety concerns with Thymalin and thymosin α1?

For Thymalin, watch for unverified identity, purity, dose and sterility; no controlled long-term human safety data. Thymosin α1 is generally well tolerated in trials; no long-term safety data for chronic use in healthy people.

Head-to-head

Thymalin vs Thymosin α1

Two thymus peptides sold for immunity and longevity, separated by evidence quality: thymosin alpha-1 is an approved drug in dozens of countries, thymalin rests on one unreplicated program.

By Julian RothResearch & dataUpdated October 2026

Short answer

Both have human clinical data behind them, which makes the goal the real difference between Thymalin and thymosin α1. For a reader focused on immune restoration and longevity, Thymalin is the relevant choice; thymosin α1 is marketed for immune support. On access, Thymalin is sold gray-market as a research chemical, while thymosin α1 is dispensed by compounding pharmacies.

Thymalin

Clinical data

Marketed for immune restoration and longer life, but the supporting science is old, small, and almost entirely from one Russian program — and unreplicated.

Full Thymalin evidence review

Thymosin α1

Zadaxin

Clinical data

An approved immunomodulator in dozens of countries (for hepatitis, sepsis and severe infection, supervised) — but not FDA-approved, not the same as TB-500, and not the anti-aging injectable sold online.

Full Thymosin α1 evidence review

Thymalin vs Thymosin α1: head to head

FDA status / approved use: Thymalin
Used in Russia as an immunomodulator; not FDA-approved, sold as a gray-market research-use-only injectable
Thymosin α1
Approved as Zadaxin in dozens of countries; not FDA-approved in the US
Marketed for: Thymalin
Immune restoration, longevity
Thymosin α1
Immune support (sold for 'anti-aging')
Outcome areas: Thymalin
Immune function / inflammation; Longevity / lifespan
Thymosin α1
Immune function / inflammation; Longevity / lifespan
Evidence grade: Thymalin
Clinical data
Thymosin α1
Clinical data
How it works: Thymalin
Polypeptide extract of thymus tissue used as an immunomodulator
Thymosin α1
Thymic peptide that tunes T-cell maturation and immune signaling
Route and dosing: Thymalin
Injection
Thymosin α1
Injection
Headline human result: Thymalin
Mortality fell 2.0- to 2.1-fold vs control in one program's 6–8 year cohort of 266 elderly people; never independently replicated
Thymosin α1
90-day transplant-free survival 75.0% vs 53.4% in a 2022 trial in hepatitis B liver failure
Strongest evidence: Thymalin
Khavinson, Neuro Endocrinol Lett 2003Thymalin evidence reviewPubMed 14523363
Thymosin α1
ETASS sepsis RCT, Crit Care 2013Thymosin α1 evidence reviewPubMed 23327199
Key safety signal: Thymalin
Unverified identity, purity, dose and sterility; no controlled long-term human safety data
Thymosin α1
Generally well tolerated in trials; no long-term safety data for chronic use in healthy people
How it is obtained: Thymalin
Sold gray-market as a research chemical; no approved or legitimately compounded human product
Thymosin α1
Prescribed and dispensed by compounding pharmacies; legality varies by compound

	Thymalin	Thymosin α1
FDA status / approved use	Used in Russia as an immunomodulator; not FDA-approved, sold as a gray-market research-use-only injectable	Approved as Zadaxin in dozens of countries; not FDA-approved in the US
Marketed for	Immune restoration, longevity	Immune support (sold for 'anti-aging')
Outcome areas	Immune function / inflammation; Longevity / lifespan	Immune function / inflammation; Longevity / lifespan
Evidence grade	Clinical data	Clinical data
How it works	Polypeptide extract of thymus tissue used as an immunomodulator	Thymic peptide that tunes T-cell maturation and immune signaling
Route and dosing	Injection	Injection
Headline human result	Mortality fell 2.0- to 2.1-fold vs control in one program's 6–8 year cohort of 266 elderly people; never independently replicated	90-day transplant-free survival 75.0% vs 53.4% in a 2022 trial in hepatitis B liver failure
Strongest evidence	Khavinson, Neuro Endocrinol Lett 2003Thymalin evidence reviewPubMed 14523363	ETASS sepsis RCT, Crit Care 2013Thymosin α1 evidence reviewPubMed 23327199
Key safety signal	Unverified identity, purity, dose and sterility; no controlled long-term human safety data	Generally well tolerated in trials; no long-term safety data for chronic use in healthy people
How it is obtained	Sold gray-market as a research chemical; no approved or legitimately compounded human product	Prescribed and dispensed by compounding pharmacies; legality varies by compound

marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.

Clinical data:: Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).

Our verdict

Thymosin alpha-1 (Zadaxin) is a real immunomodulator, approved in dozens of countries but not FDA-approved in the United States, with a genuine supervised evidence base in chronic hepatitis B and C, severe sepsis, and serious infection. Thymalin's reputation rests largely on a single research program's multi-year elderly-cohort mortality report that no independent laboratory has replicated, with most supporting studies old, small, and published in niche or Russian-language journals. That is a real gap in evidence quality and it should be said plainly. Neither supports the anti-aging pitch: thymosin alpha-1's trials were in patients who were already ill, and in the US anything you can buy is compounded or research material rather than the approved drug.

Thymalin fits if

Thymalin makes sense to read only as the weaker sibling of the Khavinson bioregulator program, interesting as a hypothesis and unsupported as a longevity therapy.

Thymosin α1 fits if

Thymosin alpha-1 is the one with a real clinical evidence base, but it belongs to clinicians treating hepatitis, sepsis, or severe infection, not to healthy adults buying vials online.

Thymalin vs Thymosin α1: common questions

Is either Thymalin or thymosin α1 FDA-approved?: No. Thymalin is used in Russia as an immunomodulator; not FDA-approved, sold as a gray-market research-use-only injectable. Thymosin α1 is approved as Zadaxin in dozens of countries; not FDA-approved in the US.
Which has stronger human evidence, Thymalin or thymosin α1?: Neither clearly. Both have human clinical data. The key source for Thymalin is Khavinson, Neuro Endocrinol Lett 2003; for thymosin α1, it is ETASS sepsis RCT, Crit Care 2013.
What are the main safety concerns with Thymalin and thymosin α1?: For Thymalin, watch for unverified identity, purity, dose and sterility; no controlled long-term human safety data. Thymosin α1 is generally well tolerated in trials; no long-term safety data for chronic use in healthy people.

Key studies behind each

Thymalin

Khavinson VKh. (2002). Peptides and Ageing. Neuro Endocrinol Lett. PubMed 12374906
Linkova N, Khavinson V, Diatlova A, Petukhov M, Vladimirova E, Sukhareva M. (2023). The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19. Int J Mol Sci. PubMed 37686182
Kuznetsova TA, Besednova NN, Zaporozhets TS, Smolina TP, Kazha AK. (2013). [Comparative study of immunomodulatory activity of peptides, tinrostim and thymalin]. Antibiot Khimioter. PubMed 24734422
Zhukova GV, Schikhlyarova AI, Barteneva TA, Shevchenko AN, Zakharyuta FM. (2018). Effect of Thymalin on the Tumor and Thymus under Conditions of Activation Therapy In Vivo. Bull Exp Biol Med. PubMed 29797130

Thymosin α1

Garaci E, Pica F, Matteucci C, et al. (2024). Phenotypic drug discovery: a case for thymosin alpha-1. Front Med (Lausanne). PubMed 38903817
Matteucci C, Minutolo A, Pollicita M, et al. (2010). Transcription profile of human lymphocytes following in vitro treatment with thymosin alpha-1. Ann N Y Acad Sci. PubMed 20536445
Chen JF, Wu W, Yang J, et al. (2022). Safety and efficacy of Thymosin α1 in the treatment of hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial. Hepatol Int. PubMed 35616850
Peng D, Wang Z, Chen S, et al. (2020). The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol. PubMed 33076834

The full evidence reviews

Thymalin: the honest evidence behind the thymus-peptide immunity and longevity claims
Marketed for immune restoration and longer life. The supporting science is old, small, and almost entirely from one Russian program — and unreplicated.
Updated August 2026
Thymosin alpha-1 peptide: benefits, evidence and how it's used
A real immune drug abroad, read against the wellness pitch. Tα1 (brand Zadaxin) is an approved immunomodulator in dozens of countries — for hepatitis, sepsis and severe infection, supervised. It is not FDA-approved, not the same as TB-500, and not the general anti-aging injectable sold online. The honest evidence, dosing and side-effect read.
Updated October 2026

Where to get it

Where to get peptide therapy

Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm Thymalin availability before ordering.

Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.

Compare all 204 peptide-therapy providers →

Provider reviews we publish: WoodworkYourHealthRxYOURx HealthYouth & SoulbmiMDBrightmeds

Related comparisons

KPV vs Thymosin α1